Rheumatoid arthritis associated cytokines and therapeutics modulate immune checkpoint receptor expression on T cells

IntroductionWe investigated the impact of rheumatoid arthritis (RA) associated cytokines and standard of care (SOC) RA therapeutics on immune checkpoint receptor (IR) expression on T cells to gain insights to disease pathology and therapeutic avenues.MethodsWe assessed IR expression by flow cytometr...

Full description

Saved in:
Bibliographic Details
Main Authors: Dana Emerson, Eve Merriman, Pia P. Yachi
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1534462/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832086911542362112
author Dana Emerson
Eve Merriman
Pia P. Yachi
author_facet Dana Emerson
Eve Merriman
Pia P. Yachi
author_sort Dana Emerson
collection DOAJ
description IntroductionWe investigated the impact of rheumatoid arthritis (RA) associated cytokines and standard of care (SOC) RA therapeutics on immune checkpoint receptor (IR) expression on T cells to gain insights to disease pathology and therapeutic avenues.MethodsWe assessed IR expression by flow cytometry on T cell receptor activated T cells cultured in the presence of exogenously added single cytokines or RA patient synovial fluid. We also assessed RA synovial fluid stimulated samples in the presence of various single cytokine neutralizing antibodies or SOC therapeutics, including glucocorticoids, TNF, IL-6 receptor and JAK inhibitors. In addition to IR expression, we measured the impact on cytokine secretion profiles.ResultsRA-associated cytokines modulated IR expression, suggesting a role for these cytokines in regulation of disease pathology. By dissecting the influence of various inflammatory drivers within the RA inflammatory milieu, we discovered distinct regulation of IR expression by various cytokines including IL-10, IFNα/β, and TNF. Specifically, increased expression of TIM-3, PD-1, LAG-3 and CD28 in response to RA synovial fluid was driven by key cytokines including IL-6, IL-10, IL-12, IFNs, and TNF. In addition, SOC RA therapeutics such as glucocorticoids and TNF inhibitors modulated IR and cytokine expression in the presence of RA synovial fluid.ConclusionsThis study points to an important and intricate relationship between cytokines and IRs in shaping immune responses in autoimmune pathology. The modulation of IR expression by RA-associated cytokines and SOC therapeutics provides new insights for the use of targeted treatments in managing RA pathology.
format Article
id doaj-art-39efdbbbc0714f6bb3642b74dca5a723
institution Kabale University
issn 1664-3224
language English
publishDate 2025-02-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj-art-39efdbbbc0714f6bb3642b74dca5a7232025-02-06T08:52:02ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-02-011610.3389/fimmu.2025.15344621534462Rheumatoid arthritis associated cytokines and therapeutics modulate immune checkpoint receptor expression on T cellsDana EmersonEve MerrimanPia P. YachiIntroductionWe investigated the impact of rheumatoid arthritis (RA) associated cytokines and standard of care (SOC) RA therapeutics on immune checkpoint receptor (IR) expression on T cells to gain insights to disease pathology and therapeutic avenues.MethodsWe assessed IR expression by flow cytometry on T cell receptor activated T cells cultured in the presence of exogenously added single cytokines or RA patient synovial fluid. We also assessed RA synovial fluid stimulated samples in the presence of various single cytokine neutralizing antibodies or SOC therapeutics, including glucocorticoids, TNF, IL-6 receptor and JAK inhibitors. In addition to IR expression, we measured the impact on cytokine secretion profiles.ResultsRA-associated cytokines modulated IR expression, suggesting a role for these cytokines in regulation of disease pathology. By dissecting the influence of various inflammatory drivers within the RA inflammatory milieu, we discovered distinct regulation of IR expression by various cytokines including IL-10, IFNα/β, and TNF. Specifically, increased expression of TIM-3, PD-1, LAG-3 and CD28 in response to RA synovial fluid was driven by key cytokines including IL-6, IL-10, IL-12, IFNs, and TNF. In addition, SOC RA therapeutics such as glucocorticoids and TNF inhibitors modulated IR and cytokine expression in the presence of RA synovial fluid.ConclusionsThis study points to an important and intricate relationship between cytokines and IRs in shaping immune responses in autoimmune pathology. The modulation of IR expression by RA-associated cytokines and SOC therapeutics provides new insights for the use of targeted treatments in managing RA pathology.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1534462/fullcheckpoint receptorcytokineT cellrheumatoid arthritisadalimumabtofacitinib
spellingShingle Dana Emerson
Eve Merriman
Pia P. Yachi
Rheumatoid arthritis associated cytokines and therapeutics modulate immune checkpoint receptor expression on T cells
Frontiers in Immunology
checkpoint receptor
cytokine
T cell
rheumatoid arthritis
adalimumab
tofacitinib
title Rheumatoid arthritis associated cytokines and therapeutics modulate immune checkpoint receptor expression on T cells
title_full Rheumatoid arthritis associated cytokines and therapeutics modulate immune checkpoint receptor expression on T cells
title_fullStr Rheumatoid arthritis associated cytokines and therapeutics modulate immune checkpoint receptor expression on T cells
title_full_unstemmed Rheumatoid arthritis associated cytokines and therapeutics modulate immune checkpoint receptor expression on T cells
title_short Rheumatoid arthritis associated cytokines and therapeutics modulate immune checkpoint receptor expression on T cells
title_sort rheumatoid arthritis associated cytokines and therapeutics modulate immune checkpoint receptor expression on t cells
topic checkpoint receptor
cytokine
T cell
rheumatoid arthritis
adalimumab
tofacitinib
url https://www.frontiersin.org/articles/10.3389/fimmu.2025.1534462/full
work_keys_str_mv AT danaemerson rheumatoidarthritisassociatedcytokinesandtherapeuticsmodulateimmunecheckpointreceptorexpressionontcells
AT evemerriman rheumatoidarthritisassociatedcytokinesandtherapeuticsmodulateimmunecheckpointreceptorexpressionontcells
AT piapyachi rheumatoidarthritisassociatedcytokinesandtherapeuticsmodulateimmunecheckpointreceptorexpressionontcells